發(fā)布時(shí)間:
2022
-
03
-
14
點(diǎn)擊次數(shù):
0
所屬職位：
總裁
所屬公司：
杭州多禧生物
個(gè)人簡介：
趙詠新是美國伊利諾依大學(xué)博士。在康奈爾大學(xué)和紀(jì)念斯隆凱琳癌癥中心完成2年博士后工作后，在美國夢山都公司、Pharmacia和美國ImmunoGen公司從事藥物研發(fā)工作15年。特別是作為核心成員或項(xiàng)目負(fù)責(zé)人參與了上市藥物T-DM1研發(fā)工藝優(yōu)化以及多個(gè)ADC藥物的設(shè)計(jì)、研發(fā)和工藝優(yōu)化工作。趙博士于2013年同原ImmunoGen的幾位上下游合作的資深科學(xué)家全職回國創(chuàng)辦杭州多禧生物科技有限公司，從事新一代ADC藥物研發(fā)工作。目前杭州多禧研發(fā)的17款新一代ADC藥物分別處在臨床試驗(yàn)、中美等國申報(bào)、安評(píng)、中試優(yōu)化、藥理/藥學(xué)/藥代/毒代評(píng)價(jià)等等不同階段。趙博士2014年入選國家人才計(jì)劃。幾年來杭州多禧生物榮獲“中國留學(xué)人員創(chuàng)業(yè)園【最具投資價(jià)值企業(yè)】”，“浙江省領(lǐng)軍型創(chuàng)新創(chuàng)業(yè)團(tuán)隊(duì)”，2015年科技部火炬杯創(chuàng)新創(chuàng)業(yè)大賽浙江賽區(qū)生物醫(yī)藥總決賽第一名，全國生物醫(yī)藥行業(yè)總決賽第二名”等榮譽(yù)。趙博士是“J. Med. Chem.”，“ACS Med. Chem. Lett”和“Bioconj. Chem”期刊的特聘審稿人。其本人多次受邀參加國家、省和市生物醫(yī)藥科技項(xiàng)目和人才計(jì)劃的評(píng)審工作。Robert Zhao btained a PhD from the University of Illinois, USA. After completing 2 years of post-doctoral work at Cornell University and Memorial Sloan-Kettering Cancer Center, he spent 15 years in R&D drug at Montserrat, Pharmacia and ImmunoGen, Inc. In particular, he was involved as a core member or project leader in R&D and process optimization of the marketed T-DM1 drug and several other ADC drugs for clinical trials. In 2013, Dr. Zhao, together with several senior scientists from the former ImmunoGen teams, returned to China full-timely to establish Hangzhou DAC Biotechnology Co. At present, the 17 new generation ADC drugs developed by Hangzhou DAC are in different stages of clinical trial, IND in China, the United States and several other countries, safety evaluation, pilot scale optimization, and efficacy /PK / PD / TK evaluations. Dr. Zhao was selected as a national talent program in 2014. In the past few years, Hangzhou DAC Biotechnology has been awarded as 'Most Valuable Enterprise for Investment in China by the Overseas Chinese Entrepreneurship Parks', 'Leading Innovation and Entrepreneurship Team of Zhejiang Province', “The first place in Zhejiang and The second place nationally in competition for the National Ministry of Science and Technology Torch Cup Innovation and Entrepreneurship in the biomedical science in 2015”. Dr. Zhao is a reviewer for the journals of 'J. Med. Chem.”, “ACS Med. Chem. Lett.' and 'Bioconj Chem”. He has been invited as judges for national, provincial and municipal biomedical science and technology projects and talent programs for many times.